Sign In
Buy BIIB
$209.03
+9.88 (+4.96%)
At Close: Jul 13, 2026
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
05:36pm, Monday, 13'th Jul 2026
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
03:02pm, Monday, 13'th Jul 2026
The U.S. FDA on Monday approved an at-home starting dose of Eisai's and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiv
Stock Market Today, July 13: Energy Stocks Cushion Dow as Tech Slides on Geopolitical Tensions
12:14pm, Monday, 13'th Jul 2026
Energy names help cushion the Dow as oil jumps on U.S.-Iran tensions and investors brace for key earnings and inflation data, today, July 13, 2026.
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer's Drug Study Details
08:15am, Monday, 13'th Jul 2026
Biogen stock receives a bullish upgrade based on expectations the market will cheer the company's detailed data on its experimental Alzheimer's drug.
Futures are trading lower as we get ready for the start of second-quarter earnings this week, after a solid winning week on Wall Street.
This Biogen Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
07:07am, Monday, 13'th Jul 2026
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
LEQEMBIÂ Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and CAMBRIDGE,
Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again
01:11pm, Tuesday, 07'th Jul 2026
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
04:02am, Saturday, 04'th Jul 2026
Biogen struggled in recent years after a major blockbuster lost exclusivity. The company's new focus on growth is bearing fruit -- and the latest acquisition strengthens Biogen's position in the key a
Amgen or Biogen: Which Biotech Stock Appears Better Poised?
10:05am, Wednesday, 01'st Jul 2026
AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.
New Strong Sell Stocks for June 30th
06:11am, Tuesday, 30'th Jun 2026
BBIB, BGSI and CLCGY have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2026.
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
12:11pm, Monday, 29'th Jun 2026
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?
09:11am, Monday, 29'th Jun 2026
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB
08:00am, Monday, 29'th Jun 2026
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Block & Leviton LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed cl
